not losing weight retatrutide 💉 is the most powerful loss drug ever trialled. 28.7 percent average body weight loss in 68 weeks. Some participants lost over 30 percent of their starting body weight. The Retatrutide for weight loss: Study

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

The risk of bacterial growth is extremely high after the first puncture

The skin becomes stronger, thicker, and more resilient against future damage

Personalized Nutrition Plan Designed to pair with your GLP-1 protocol protein-targeted, blood sugar stabilized, and muscle preserving

You may experience: Nausea: nausea is a common side effect with many GLP-1 receptor agonists, but its severity can vary between individuals

If you took Ozempic, Wegovy, Mounjaro, or similar drugs and developed persistent vomiting, gastroparesis, or intestinal issues requiring medical care, you likely qualify